BBNX — Beta Bionics, Inc. Stock Price, Chart & AI Report

Negative Oct 14, 2026 • 22:42 UTC GlobeNewswire Inc. • Robbins Llp

Beta Bionics, Inc. Class Action Reminder - Robbins LLP Encourages BBNX Investors to Contact the Firm for Information About Their Rights

Robbins LLP reminds investors of a class action lawsuit against Beta Bionics (BBNX) for allegedly misleading investors about the safety and efficacy of its iLet insulin pump. The company failed to disclose serious FDA concerns about device malfunctions causing dangerously high insulin doses and hypoglycemic events. Stock fell from $31.99 to $12.89 per share between January and February 2026 following FDA warning letter disclosures.

BBNX CELH DKS class action lawsuit securities fraud FDA warning letter insulin pump device malfunction

Sentiment note

Company is subject to a securities class action lawsuit for material misrepresentation regarding device safety and efficacy. FDA identified serious malfunctions causing dangerous insulin overdoses. Stock declined 60% during the class period. Company failed to disclose thousands of complaints and hundreds of life-threatening events.

Negative Oct 14, 2026 • 17:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Beta Bionics, Inc. for alleged securities fraud. The complaint alleges that the company made materially false and misleading statements regarding FDA observations about its iLet Bionic Pancreas insulin pump, including undisclosed quality management deficiencies and unreported serious customer injuries. Investors who purchased Beta Bionics securities between July 30, 2025 and February 24, 2026 are encouraged to join the case, with a lead plaintiff deadline of November 3, 2026.

BBNX class action lawsuit securities fraud FDA violations iLet Bionic Pancreas investor harm material misstatements quality management deficiencies

Sentiment note

The company is the subject of a securities fraud class action lawsuit alleging material misstatements and omissions regarding FDA observations, quality management system deficiencies, and unreported serious customer injuries related to its flagship iLet product. These allegations suggest significant regulatory and safety concerns that were not properly disclosed to investors.

Negative Oct 14, 2026 • 03:45 UTC GlobeNewswire Inc. • Kahn Swick & Foti, Llc

Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

A class action securities lawsuit has been filed against Beta Bionics, Inc. for allegedly making false statements about its iLet Bionic Pancreas insulin pump. The lawsuit claims the device's automated dosing algorithm malfunctioned, delivering dangerously high insulin levels causing hypoglycemic events, and that the company failed to disclose thousands of complaints to the FDA. Investors who purchased stock between July 30, 2025 and February 24, 2026 can apply to be lead plaintiff by November 3, 2026.

BBNX class action lawsuit securities fraud Beta Bionics iLet Bionic Pancreas insulin pump FDA medical device

Sentiment note

The company faces serious allegations of material misstatements regarding device safety, failure to disclose thousands of customer complaints to the FDA, and inadequate corrective actions. The lawsuit alleges the iLet device caused life-threatening hypoglycemic events, representing significant operational and regulatory failures that directly harm investor confidence and company valuation.

Negative Oct 14, 2026 • 03:24 UTC GlobeNewswire Inc. • Kahn Swick & Foti, Llc

AEVEX Corp. Notice of October 20, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Kahn Swick & Foti, LLC announces class action securities lawsuits against AEVEX Corp., Beta Bionics, Inc., and York Space Systems, Inc. The primary case alleges that AEVEX and its executives concealed a pre-arranged plan to prematurely override a 180-day lock-up commitment, allowing Madison to sell shares and generate over $200 million through a secondary offering. Investors who purchased shares during the class periods have until the specified deadlines to request lead plaintiff status.

AVEX BBNX YSS class action lawsuit securities fraud lock-up violation IPO secondary offering

Sentiment note

Company is subject to a class action securities fraud lawsuit, indicating alleged misconduct affecting investors.

Negative Oct 13, 2026 • 20:52 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines – BBNX

Pomerantz Law Firm has filed a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) alleging securities fraud related to its iLet insulin pump device. The company allegedly misrepresented FDA concerns and failed to properly report thousands of patient complaints. The lawsuit follows significant stock price declines after the FDA issued a warning letter in February 2026, revealing more serious safety and reporting issues than Beta Bionics had previously disclosed. Investors have until November 3, 2026, to join the class action.

BBNX class action lawsuit securities fraud FDA warning letter insulin pump patient complaints stock price decline medical device

Sentiment note

Company faces class action lawsuit for alleged securities fraud and misrepresentation of FDA concerns regarding its iLet insulin pump. Stock declined approximately 37% on January 8, 2026, following disclosure of over 18,000 patient complaints out of less than 30,000 patients. FDA warning letter revealed serious safety reporting violations and potential life-threatening risks that were not properly disclosed to investors.

Negative Oct 12, 2026 • 22:29 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

A securities class action lawsuit has been filed against Beta Bionics, Inc. (BBNX) for allegedly making false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA raised serious concerns about the device malfunctioning and delivering dangerously high insulin doses, causing hypoglycemic events. The company allegedly failed to implement meaningful corrective actions. Investors who purchased BBNX stock between July 30, 2025 and February 24, 2026 may be eligible for compensation. The lead plaintiff deadline is November 3, 2026.

BBNX securities class action Beta Bionics iLet Bionic Pancreas FDA violations insulin pump malfunction investor compensation lead plaintiff deadline

Sentiment note

The company is facing a securities class action lawsuit for making materially false and misleading statements about its insulin delivery device. The FDA identified thousands of complaints including hundreds of life-threatening events caused by the device malfunctioning and delivering dangerously high insulin doses. The company allegedly failed to implement corrective actions, indicating serious product safety and compliance failures that resulted in investor losses.

Negative Oct 10, 2026 • 01:28 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A LEADING LAW FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

Rosen Law Firm is urging investors who purchased Beta Bionics common stock between July 30, 2025 and February 24, 2026 to join a securities class action lawsuit. The lawsuit alleges that Beta Bionics made materially false and misleading statements about its iLet Bionic Pancreas insulin pump, which the FDA found was malfunctioning and dosing patients with dangerously high insulin levels. The firm claims thousands of complaints were filed with the FDA, contradicting defendants' assertions that issues were benign. The lead plaintiff deadline is November 3, 2026.

BBNX securities class action Beta Bionics iLet Bionic Pancreas FDA insulin pump investor lawsuit lead plaintiff deadline

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misstatements about its insulin delivery device. The FDA identified serious safety issues including device malfunctions, dangerously high insulin dosing, and thousands of complaints. The company allegedly failed to implement meaningful corrective actions, resulting in investor damages.

Negative Oct 9, 2026 • 22:11 UTC GlobeNewswire Inc. • Hagens Berman

BBNX INVESTOR DEADLINE: Beta Bionics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - HBSS

Beta Bionics (NASDAQ: BBNX) faces a securities class action lawsuit for allegedly misleading investors about its iLet automated insulin delivery system. The company concealed thousands of safety complaints, including life-threatening hypoglycemic events, and failed to report them to the FDA as required. An FDA warning letter in February 2026 revealed the violations, causing significant shareholder losses during the class period of July 30, 2025 to February 24, 2026.

BBNX securities class action FDA warning letter iLet insulin delivery system safety complaints investor losses regulatory violations medical device

Sentiment note

The company is accused of deliberately concealing thousands of safety complaints and failing to report serious adverse events to the FDA. Management allegedly misled investors about the severity of FDA inspection findings. The resulting FDA warning letter and securities lawsuit indicate serious regulatory and legal violations that caused substantial shareholder losses.

Negative Oct 7, 2026 • 01:37 UTC GlobeNewswire Inc. • Kahn Swick & Foti, Llc

Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

A class action securities lawsuit has been filed against Beta Bionics, Inc. for allegedly making false statements about its iLet Bionic Pancreas insulin pump. The lawsuit claims the device's automated dosing algorithm malfunctioned, delivering dangerously high insulin levels causing hypoglycemic events, and that the company failed to disclose thousands of complaints to the FDA. Investors who purchased stock between July 30, 2025 and February 24, 2026 can apply to be lead plaintiff by November 3, 2026.

BBNX class action lawsuit securities fraud Beta Bionics iLet Bionic Pancreas insulin pump FDA medical device

Sentiment note

The company faces serious allegations of failing to disclose malfunctioning medical devices causing life-threatening hypoglycemic events, thousands of unreported customer complaints, and FDA violations. These material misrepresentations and omissions resulted in investor losses during the class period.

Negative Oct 6, 2026 • 11:00 UTC GlobeNewswire Inc. • Holzer & Holzer, Llc

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Unicycive Therapeutics, Inc. (UNCY), Hims & Hers Health, Inc. (HIMS), and Beta Bionics, Inc. (BBNX) Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Unicycive Therapeutics, Hims & Hers Health, and Beta Bionics. The lawsuits allege materially false statements and non-disclosure of material facts regarding regulatory risks, deceptive billing practices, data sharing, and device safety issues. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by November 2-3, 2026.

UNCY HIMS BBNX shareholder class action lead plaintiff deadline securities litigation material misstatements investor losses

Sentiment note

Company faces class action lawsuit alleging false statements regarding safety of its iLet Bionic Pancreas insulin pump, indicating potential product safety concerns and investor deception.

Negative Oct 5, 2026 • 18:40 UTC GlobeNewswire Inc. • Glancy Prongay Wolke & Rotter Llp

Deadline Alert: Beta Bionics, Inc. (BBNX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

A class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging securities fraud for failing to disclose material information about FDA safety violations and product issues. The company allegedly omitted over 18,000 complaints including life-threatening hypoglycemic events from FDA reports and misrepresented the severity of FDA observations. The lawsuit covers investors who purchased shares between July 30, 2025 and February 24, 2026, with a November 3, 2026 deadline to file as lead plaintiff.

BBNX securities fraud class action lawsuit FDA warning letter material misstatement product safety investor losses disclosure violations

Sentiment note

The company faces a securities fraud class action lawsuit for allegedly making materially false statements and failing to disclose critical FDA safety violations, including over 18,000 unreported complaints involving life-threatening incidents. Multiple stock price declines (37%, 6.5%, and 3.73%) followed disclosure of these issues, indicating significant investor harm and loss of confidence.

Negative Oct 3, 2026 • 12:35 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

A securities class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging the company made materially false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA reportedly raised serious safety concerns including device malfunctions and dangerously high insulin dosing causing hypoglycemic events. The lawsuit claims Beta Bionics failed to implement meaningful corrective actions despite thousands of complaints. Investors who purchased stock between July 30, 2025 and February 24, 2026 may be eligible for compensation, with a November 3, 2026 deadline to serve as lead plaintiff.

BBNX securities class action FDA safety concerns insulin pump medical device investor compensation misleading statements

Sentiment note

The company faces a securities class action lawsuit alleging material misrepresentations regarding the safety of its flagship iLet insulin pump device. Allegations include thousands of FDA complaints, device malfunctions causing dangerous insulin overdoses, and failure to implement corrective actions. These serious safety and compliance issues resulted in investor losses.